^
    9ms
    A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=34, Terminated, Shanghai East Hospital | N=64 --> 34 | Trial completion date: Jun 2026 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jul 2023; Both the sponsors and collaborator are considering terminating the study
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    CLDN18 (Claudin 18)
    |
    LCAR-C18S
    1year
    LB1908-1001: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=56, Recruiting, Legend Biotech USA Inc | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    LCAR-C18S
    1year
    LB1908-1001: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, Legend Biotech USA Inc | Initiation date: Jan 2023 --> Apr 2023
    Trial initiation date • CAR T-Cell Therapy • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    LCAR-C18S
    over1year
    A phase 1, open-label, dose escalation and expansion, multicenter study of claudin 18.2-targeted chimeric antigen receptor T-cells in patients with unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, esophageal, or pancreatic adenocarcinoma. (ASCO-GI 2023)
    Subjects may receive optional bridging therapy followed by lymphodepleting chemotherapy with fludarabine 30 mg/m2/day and cyclophosphamide 300 mg/m2/day for 3 days...Secondary and exploratory endpoints include: objective response rate, disease control rate, duration of response, progression-free survival, characterization of PK by CAR-positive T cell counts, CAR transgene level in blood, effusions, and target tissues, and evaluation of immunogenicity by presence of anti-LB1908 antibodies. Acknowledgments: This study is funded by Legend Biotech USA Inc. Clinical trial information: NCT05539430.
    Clinical • P1 data • CAR T-Cell Therapy • IO biomarker • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    cyclophosphamide • fludarabine IV • LCAR-C18S
    over1year
    Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, Legend Biotech USA Inc
    New P1 trial • CAR T-Cell Therapy
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    LCAR-C18S
    almost2years
    A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=64, Recruiting, Shanghai East Hospital | N=34 --> 64 | Trial completion date: Nov 2024 --> Jun 2026 | Trial primary completion date: Nov 2022 --> Dec 2023
    Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
    |
    LCAR-C18S
    over3years
    A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Gastric Cancer (clinicaltrials.gov)
    P1, N=34, Recruiting, Shanghai East Hospital | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • CAR T-Cell Therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    LCAR-C18S
    almost4years
    A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Gastric Cancer (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Shanghai East Hospital
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    LCAR-C18S